Hematologic and Hemato-Oncologic Aspects of Gaucher Disease

S88 Volume 29 Supplement C Hematologic and Hemato-Oncologic Aspects of Gaucher Disease Derralynn Hughes, MA, DPhil, MRCP, MRCPath1; Maria Domenica Cappellini, MD2; Marc Gabriel Berger, MD, PhD3; Jan Van Droogenbroeck, MD4; Maaike de Fost, MD5; Dragana Janic, MD, PhD6; Theodore Marinakis, MD, PhD7; Hanna Rosenbaum, MD8; Jesus Villarubia, MD, PhD9; Elena Zhukovskaya, MD10; and Carla Hollak, MD5 1Lysosomal Storage Diseases Unit, Department of Academic Haematology, Royal Free Hospital and University College Medical School, London, United Kingdom; 2Department of Internal Medicine, Policlinico Foundation IRCCS, University of Milan, Milan, Italy; 3Department of Hematology, CHU Hotel-Dieu, Clermont-Ferrand, France; 4Department of Hematology, AZ St. Jan AV, Brugge, Belgium; 5Department of Internal Medicine, Division of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 6University Children’s Hospital, University of Belgrade, Belgrade, Serbia; 7The Hellenic Collaborative Working Group of Hematologists on Gaucher Disease, Athens, Greece; 8Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Haifa, Israel; 9Ramon and Cajal Hospital, Servicio de Hematologia, Madrid, Spain; and 10State Medical Academy, Chelyabinsk, Russia